The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants
Charles V. Pollack, John Fanikos(General Department of Preventive Medicine), Alex Frost, Carol L. Clark(Beaumont Hospital, Royal Oak), Steven H. Silber(NewYork–Presbyterian Brooklyn Methodist Hospital), W. Frank Peacock(Hennepin Healthcare Research Institute), Babak S. Jahromi, Geno J. Merli(Thomas Jefferson University), Charles L. Johnson(Southmead Hospital), James D. Douketis(McMaster University), Gregory J. Fermann(Harvard University), Todd C. Villines(University of Virginia Health System), Richard A. Bernstein(Northwestern University), Gregory Fiore
Cited by 17
Related Papers
Cryptogenic Stroke and Underlying Atrial Fibrillation
|New England Journal of Medicine|2014|2.2k
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
|New England Journal of Medicine|2017|1.1k
Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction
|Circulation|2009|1k
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
|New England Journal of Medicine|2019|823
MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study
|The Lancet Neurology|2012|775